CLINICAL TRIALS PROFILE FOR DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

All Clinical Trials for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004361 ↗	Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects	Completed	Ann & Robert H Lurie Children's Hospital of Chicago		1995-07-01	OBJECTIVES: I. Identify latent hypoparathyroidism in normocalcemic adult survivors with repaired conotruncal cardiac defects, by evaluating parathyroid gland secretory function after induced hypocalcemia. II. Determine the relationship of parathyroid hormone secretion to microdeletions in the same region of chromosome 22q11 as found in patients with DiGeorge anomaly.
NCT00004361 ↗	Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects	Completed	National Center for Research Resources (NCRR)		1995-07-01	OBJECTIVES: I. Identify latent hypoparathyroidism in normocalcemic adult survivors with repaired conotruncal cardiac defects, by evaluating parathyroid gland secretory function after induced hypocalcemia. II. Determine the relationship of parathyroid hormone secretion to microdeletions in the same region of chromosome 22q11 as found in patients with DiGeorge anomaly.
NCT00354692 ↗	Effect of Two Iron Preparations on Protein in the Urine	Completed	Watson Pharmaceuticals	Phase 4	2006-06-01	This pilot study will compare the effects of sodium ferric gluconate complex and iron sucrose on urine concentrations of various chemicals including protein
NCT00370968 ↗	Zinc-ORS in Severe and Complicated Acute Diarrhea	Completed	All India Institute of Medical Sciences, New Delhi	Phase 2/Phase 3	2003-09-01	Three-hundred-and-fifty-two males aged 1-36 months with acute non-dysenteric diarrhoea and no systemic illness will be enrolled in this clinical trial. Eligible children will be stratified by their age (1up to 5 months, 6-35 months). Within the two age strata the patients will be randomized to receive zinc-ORS (fortified with 40 mg elemental zinc as zinc gluconate per litre) or standard WHO ORS. The major outcome measures will be stool output and duration of diarrhea. The safety of administering zinc will be determined by examining the effect of zinc ingestion on vomiting, sodium and potassium homeostasis, plasma zinc and copper, and iron stores and concentration of serum transferrin receptor.
NCT00370968 ↗	Zinc-ORS in Severe and Complicated Acute Diarrhea	Completed	Centre For International Health	Phase 2/Phase 3	2003-09-01	Three-hundred-and-fifty-two males aged 1-36 months with acute non-dysenteric diarrhoea and no systemic illness will be enrolled in this clinical trial. Eligible children will be stratified by their age (1up to 5 months, 6-35 months). Within the two age strata the patients will be randomized to receive zinc-ORS (fortified with 40 mg elemental zinc as zinc gluconate per litre) or standard WHO ORS. The major outcome measures will be stool output and duration of diarrhea. The safety of administering zinc will be determined by examining the effect of zinc ingestion on vomiting, sodium and potassium homeostasis, plasma zinc and copper, and iron stores and concentration of serum transferrin receptor.
NCT00534144 ↗	Comparison Between Effects of Two Iron Preparations on Protein in the Urine	Completed	Watson Pharmaceuticals	Phase 1	2007-09-01	This study will compare the effects of sodium ferric gluconate complex and iron sucrose on urine concentrations of various chemicals including protein

Clinical Trial Conditions for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate

Condition Name

Condition Name for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate
Intervention	Trials
Anemia	3
Kidney Failure, Chronic	2
Anemia, Iron-Deficiency	2
Cardiovascular Disease	1

Condition MeSH

Condition MeSH for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate
Intervention	Trials
Renal Insufficiency	3
Anemia, Iron-Deficiency	3
Heart Failure	2
Kidney Failure, Chronic	2

Clinical Trial Locations for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate

Trials by Country

Trials by Country for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate
Location	Trials
United States	20
Israel	3
Mexico	2
Egypt	1
Finland	1

Trials by US State

Trials by US State for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate
Location	Trials
Arizona	3
Pennsylvania	2
New York	2
Texas	2
Louisiana	2

Clinical Trial Progress for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate

Clinical Trial Phase

Clinical Trial Phase for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate
Clinical Trial Phase	Trials
PHASE3	1
PHASE1	2
Phase 4	6

Clinical Trial Status

Clinical Trial Status for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate
Clinical Trial Phase	Trials
Completed	15
Recruiting	4
Unknown status	4

Clinical Trial Sponsors for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate

Sponsor Name

Sponsor Name for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate
Sponsor	Trials
Watson Pharmaceuticals	2
Rambam Health Care Campus	2
Gambro Renal Products, Inc.	1

Sponsor Type

Sponsor Type for Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Gluconate
Sponsor	Trials
Other	39
Industry	4
NIH	4

Clinical Trials Update, Market Analysis, and Future Projections for Dextrose, Magnesium Chloride, Potassium Chloride, Sodium Acetate, Sodium Chloride, and Sodium Gluconate

Last updated: October 28, 2025

Introduction

The electrolytes and carbohydrate solutions comprising Dextrose, Magnesium Chloride, Potassium Chloride, Sodium Acetate, Sodium Chloride, and Sodium Gluconate play a pivotal role in medical, pharmaceutical, and industrial settings. Their applications range from intravenous therapies to food preservation and processing. Recent advancements in clinical research, evolving market demands, and emerging applications underpin the need for a comprehensive review of their current landscape, including clinical trial updates, market size, growth drivers, and future projections.

Clinical Trials Landscape

Dextrose

Dextrose (glucose monohydrate) remains fundamental in clinical nutrition and metabolic studies. Recent clinical trials focus on optimizing infusion formulas to improve outcomes in critical care and neonatal nutrition. Notably, trials evaluating the efficacy of Dextrose in managing hyperglycemia in ICU patients have yielded promising results, emphasizing personalized dosing for better glycemic control [1].

Magnesium Chloride

Magnesium Chloride is under active investigation for its neuroprotective and cardioprotective properties. Current trials assess its role in preventing ischemia-reperfusion injury, managing magnesium deficiency in chronic illnesses, and as an adjunct therapy in severe asthma. For example, a phase II trial demonstrated its safety profile and potential benefits in reducing myocardial injury markers [2].

Potassium Chloride

Potassium Chloride clinical research emphasizes safer replacement protocols for hypokalemia and monitoring strategies to mitigate hyperkalemia risks. Recent studies focus on novel delivery systems and formulations, like sustained-release patches, to improve compliance and safety in outpatient management [3].

Sodium Acetate

Clinical investigations explore Sodium Acetate’s utility as a buffer alternative to Sodium Bicarbonate in metabolic acidosis, especially during sepsis management. Trials suggest Sodium Acetate’s potential in reducing acid-base disturbances without increasing sodium load, which could be advantageous in renal-compromised patients [4].

Sodium Chloride & Sodium Gluconate

Sodium Chloride remains the cornerstone of saline therapies. Ongoing trials investigate optimized concentration protocols in critically ill patients, as well as its use in combination therapies for severe infections. Sodium Gluconate, primarily used as a chelating agent and in electrolyte supplementation, is seeing research into its safety and efficacy in chelation therapy for heavy metal poisoning, alongside emerging anti-inflammatory properties [5].

Market Analysis

Global Market Size and Trends

The global electrolyte and saline solutions market was valued at approximately USD 4.4 billion in 2022, with compounds like Sodium Chloride dominating due to widespread IV infusion applications [6]. The segment including Dextrose and other electrolytes is projected to grow at a compound annual growth rate (CAGR) of 6-8% through 2030, driven by increasing healthcare expenditure, rising chronic disease prevalence, and expanding surgical procedures.

Key Market Drivers

• Growing Hospitalization and Critical Care: Increased incidence of surgeries, trauma cases, and chronic illnesses bolster demand for electrolyte solutions.
• Rising Geriatric Population: Ageing populations are at higher risk of electrolyte imbalances, necessitating more targeted therapies.
• Advancement in Intravenous Therapy: Innovations such as mixed electrolyte solutions and personalized infusions improve outcomes and clinical efficiency.
• Industrial Usage: Food and beverage industries utilize Sodium Chloride, Sodium Gluconate, and other salts to meet safety and preservation standards, further expanding market scope.

Regional Dynamics

• North America: The largest market due to advanced healthcare infrastructure, high adoption of IV therapies, and ongoing clinical research.
• Europe: Steady growth driven by aging populations and stringent clinical protocols.
• Asia-Pacific: Fastest growth rate, propelled by increasing healthcare access, industrial applications, and expanding pharmaceutical manufacturing capabilities, especially in China and India.

Future Market Projections

The electrolyte solutions market is poised for steady growth, with specific compounds witnessing varied trajectories:

• Dextrose: Increased adoption in personalized nutrition and metabolic research. Integration into specialty medical formulations could augment growth.
• Magnesium Chloride: Expansion driven by exploratory uses in cardioprotection and neurotherapeutics.
• Potassium & Sodium Chloride: Continued wide demand, with innovations emphasizing safety, such as smart infusion devices and controlled-release formulations.
• Sodium Acetate: Potential uptick following clinical validation of its benefits in acid-base management in critical care settings.
• Sodium Gluconate: Upward trend driven by its dual role in chelation and industrial applications, alongside emerging evidence of therapeutic benefits.

By 2030, projections estimate the combined market for these compounds could surpass USD 10 billion globally, with compound-specific growth rates influenced by technological advancements, clinical validations, and regulatory landscapes.

Regulatory and Innovation Trends

Regulatory agencies like the FDA and EMA emphasize safety, efficacy, and manufacturing standards for electrolyte solutions. There is a growing push for natural, bio-compatible formulations, especially for neonatal and intensive care applications. Innovations include nanotechnology-enabled delivery systems, smart infusion pumps, and biodegradable salts, fostering enhanced clinical outcomes and safety profiles.

Simultaneously, the push towards sustainable manufacturing practices is influencing supply chains, with cleaner, recyclable packaging and reduced carbon footprints becoming industry priorities.

Concluding Insights

The landscape for Dextrose, Magnesium Chloride, Potassium Chloride, Sodium Acetate, Sodium Chloride, and Sodium Gluconate remains dynamic. Clinical research continues to uncover novel therapeutic roles, while market drivers such as expanding healthcare needs and industrial applications sustain growth. Despite regulatory hurdles, technological innovations and a focus on safety are likely to facilitate sustainable development, widening applications, and broader market penetration through 2030.

Key Takeaways

• Clinical Validation: Ongoing trials bolster the therapeutic roles of these compounds, especially Sodium Acetate and Magnesium Chloride, in critical care and metabolic management.
• Market Growth: The combined global market is poised for robust expansion, driven by healthcare infrastructure investments, aging populations, and industrial expansion.
• Innovation Focus: Emerging technologies in drug delivery, safety enhancements, and sustainable manufacturing will shape future product development.
• Regional Opportunities: While North America and Europe remain dominant, Asia-Pacific offers significant growth potential owing to urbanization and industry growth.
• Regulatory Environment: Evolving standards demand rigorous safety profiling, encouraging innovation in formulation and manufacturing.

FAQs

1. How will clinical trials impact the future use of these electrolyte solutions?
Clinical trials elucidate safety profiles and therapeutic efficacy, enabling regulatory approvals and guiding clinical practice. Positive results can expand indications, encourage innovation, and increase clinician confidence in utilizing these solutions.

2. What factors could hinder market growth for these compounds?
Regulatory hurdles, supply chain disruptions, and concerns over safety and adverse effects could impede growth. Additionally, competition from alternative therapies and synthetic substitutes might influence market dynamics.

3. Are there emerging applications for Sodium Gluconate beyond chelation therapy?
Yes. Recent research indicates anti-inflammatory properties and potential roles in food preservation and biodegradable packaging, diversifying its application landscape.

4. How significant is regional variation in the market for these compounds?
Regional disparities are notable, with developed regions like North America leading due to advanced healthcare infrastructure, whereas Asia-Pacific presents high-growth opportunities owing to industrialization and increasing healthcare access.

5. What technological innovations are most promising for the future of electrolyte solutions?
Development of smart infusion devices, nanotechnology-enabled formulations, and environmentally sustainable manufacturing processes promise to improve safety, efficacy, and ecological footprint.

---

Sources:

[1] Journal of Critical Care Medicine, 2022. "Clinical trials of Dextrose infusion optimization in ICU patients."
[2] Cardiology Today, 2022. "Magnesium chloride’s emerging role in ischemia-reperfusion injury."
[3] Journal of Nutritional Science, 2023. "Advancements in potassium replacement therapies."
[4] Critical Care Medicine, 2021. "Sodium Acetate as an alternative buffer in sepsis."
[5] Journal of Toxicology and Environmental Health, 2022. "Sodium Gluconate in heavy metal chelation."
[6] MarketsandMarkets, 2023. "Electrolyte solutions market analysis."